ArticleJournal of clinical microbiology2008
In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species.
Article in Journal of clinical microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.
- Antifungal therapy in children: an update.European journal of pediatrics · 2013Pooled it
- In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial.American journal of ophthalmology · 2014Trial
- A long non-coding RNA,mSphere · 2026Article
- A long non-coding RNA,bioRxiv : the preprint server for biology · 2026Article
- Molecular identification ofJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2022Article
- Clinical and Microbiological Characteristics of Proven Invasive Aspergillosis Due to Rare/Cryptic Species in Allogeneic Hematopoietic Stem Cell Transplant Recipients.Antimicrobial agents and chemotherapy · 2022Article
- Prognostic Scores and Azole-ResistantJournal of fungi (Basel, Switzerland) · 2021Article
- Mechanisms of triazole resistance in Aspergillus fumigatus.Environmental microbiology · 2020Review
- Molecular Identification and In Vitro Antifungal Susceptibility of Aspergillus Isolates Recovered from Otomycosis Patients in Western China.Mycopathologia · 2020Article
- 11g, a Potent Antifungal Candidate, EnhancesFrontiers in microbiology · 2020Article
- Emergence of Azole-Resistant Aspergillus fumigatus from Immunocompromised Hosts in India.Antimicrobial agents and chemotherapy · 2018Article
- Investigation of Multiple Resistance Mechanisms in Voriconazole-Resistant Aspergillus flavus Clinical Isolates from a Chest Hospital Surveillance in Delhi, India.Antimicrobial agents and chemotherapy · 2018Article
- Antifungal Susceptibility Testing of Aspergillus spp. by Using a Composite Correlation Index (CCI)-Based Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Method Appears To Not Offer Benefit over Traditional Broth Microdilution Testing.Journal of clinical microbiology · 2017Article
- Epidemiological and Genomic Landscape of Azole Resistance Mechanisms inFrontiers in microbiology · 2016Review
- Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.Antimicrobial agents and chemotherapy · 2015Article
- Cryptic and rare Aspergillus species in Brazil: prevalence in clinical samples and in vitro susceptibility to triazoles.Journal of clinical microbiology · 2014Article
- Does fungicide application in vineyards induce resistance to medical azoles in Aspergillus species?Environmental monitoring and assessment · 2014Article
- Evaluation of amphotericin B and chloramphenicol as alternative drugs for treatment of chytridiomycosis and their impacts on innate skin defenses.Applied and environmental microbiology · 2014Article
- Article
- Antifungal agents in current pediatric practice.Current infectious disease reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Few data exist to describe in vitro patterns of cross-resistance among large collections of clinical Aspergillus isolates, including those of species other than Aspergillus fumigatus. We examined 771 Aspergillus spp. clinical isolates collected from 2000 to 2006 as part of a global antifungal surveillance program (553 A. fumigatus, 76 A. flavus, 59 A. niger, 35 A. terreus, and 24 A. versicolor isolates and 24 isolates of other Aspergillus species). Antifungal susceptibility testing was performed by the Clinical and Laboratory Standards Institute (CLSI) M38-A broth dilution method with itraconazole (ITR), posaconazole (POS), ravuconazole (RAV), and voriconazole (VOR). We examined the potential for cross-resistance by using measures of correlation overall and by species. For most Aspergillus isolates (from 88% of isolates for ITR to 98% of isolates for VOR and POS), MICs of each triazole were < or = 1 microg/ml. When all 771 isolates were examined, there were statistically significant correlations for all six triazole-triazole pairs. For A. fumigatus, the strongest correlations seen were those between VOR and RAV MICs (r = 0.7) and ITR and POS MICs (r = 0.4). Similarly, for A. flavus, only VOR and RAV MICs and ITR and POS MICs demonstrated statistically significant positive correlations. We have demonstrated correlations among triazole MICs for Aspergillus, which for the most common species (A. fumigatus and A. flavus) were strongest between VOR and RAV MICs and ITR and POS MICs. However, Aspergillus species for which MICs of VOR or POS were >2 microg/ml remain extremely rare (<1% of isolates).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.